Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 4/20 | 0.43 |
| ▸ | TP53 | P04637 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CLPP | Q16740 | 2/20 | 0.41 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22845227 | 0.95 | GNRHR (0.44) | GNRHRTP53ALDH1A1CLPPREV1 | |
| SCHEMBL22845204 | 0.85 | GNRHR (0.44) | GNRHRTP53ALDH1A1MEN1KMT2A | |
| SCHEMBL22845483 | 0.83 | GNRHR (0.44) | GNRHRTP53ALDH1A1MEN1KMT2A | |
| SCHEMBL24470066 | 0.80 | ALDH1A1 (0.39) | ALDH1A1LMNAMEN1KMT2AGAA | |
| SCHEMBL22845374 | 0.80 | GNRHR (0.45) | GNRHRALDH1A1MEN1KMT2AGAA | |
| SCHEMBL22845403 | 0.79 | TP53 (0.45) | GNRHRTP53ALDH1A1LMNAMEN1 | |
| SCHEMBL22845489 | 0.79 | GNRHR (0.44) | GNRHRALDH1A1LMNAREV1MEN1 | |
| SCHEMBL22845210 | 0.78 | ALDH1A1 (0.42) | GNRHRALDH1A1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL22845209 | 0.76 | MAPT (0.42) | TP53ALDH1A1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL22845396 | 0.76 | GNRHR (0.44) | GNRHRALDH1A1MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-01-06 | — | — | US | disclosed |
| US-11136321-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | GNRHR 2198/4885TP53 1710/4885ALDH1A1 648/4885 |
| US-11136321-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | GNRHR 2198/4885TP53 1710/4885ALDH1A1 648/4885 |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | GNRHR 2198/4885TP53 1710/4885ALDH1A1 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.